Johnson & Johnson Current Ratio 2012-2026 | JNJ
Current and historical current ratio for Johnson & Johnson (JNJ) from 2012 to 2026. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Johnson & Johnson current ratio for the three months ending March 31, 2026 was 0.00.
| Johnson & Johnson Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2026-03-31 | $0.00B | 0.00 | |
| 2025-12-31 | $55.62B | $54.13B | 1.03 |
| 2025-09-30 | $54.61B | $50.87B | 1.07 |
| 2025-06-30 | $54.50B | $54.18B | 1.01 |
| 2025-03-31 | $71.55B | $56.90B | 1.26 |
| 2024-12-31 | $55.89B | $50.32B | 1.11 |
| 2024-09-30 | $53.25B | $51.76B | 1.03 |
| 2024-06-30 | $57.82B | $53.93B | 1.07 |
| 2024-03-31 | $57.00B | $48.73B | 1.17 |
| 2023-12-31 | $53.50B | $46.28B | 1.16 |
| 2023-09-30 | $53.70B | $44.37B | 1.21 |
| 2023-06-30 | $60.57B | $54.17B | 1.12 |
| 2023-03-31 | $64.39B | $60.37B | 1.07 |
| 2022-12-31 | $55.29B | $55.80B | 0.99 |
| 2022-09-30 | $65.24B | $45.54B | 1.43 |
| 2022-06-30 | $63.85B | $44.82B | 1.42 |
| 2022-03-31 | $60.42B | $43.39B | 1.39 |
| 2021-12-31 | $60.98B | $45.23B | 1.35 |
| 2021-09-30 | $59.89B | $44.56B | 1.34 |
| 2021-06-30 | $53.77B | $38.72B | 1.39 |
| 2021-03-31 | $52.53B | $40.93B | 1.28 |
| 2020-12-31 | $51.24B | $42.49B | 1.21 |
| 2020-09-30 | $57.58B | $38.85B | 1.48 |
| 2020-06-30 | $45.89B | $36.77B | 1.25 |
| 2020-03-31 | $44.23B | $33.69B | 1.31 |
| 2019-12-31 | $45.27B | $35.96B | 1.26 |
| 2019-09-30 | $44.33B | $35.16B | 1.26 |
| 2019-06-30 | $41.80B | $31.35B | 1.33 |
| 2019-03-31 | $41.99B | $29.11B | 1.44 |
| 2018-12-31 | $46.03B | $31.23B | 1.47 |
| 2018-09-30 | $47.19B | $27.44B | 1.72 |
| 2018-06-30 | $45.44B | $27.49B | 1.65 |
| 2018-03-31 | $42.77B | $27.08B | 1.58 |
| 2017-12-31 | $43.09B | $30.54B | 1.41 |
| 2017-09-30 | $41.83B | $31.81B | 1.32 |
| 2017-06-30 | $38.79B | $28.87B | 1.34 |
| 2017-03-31 | $63.35B | $25.12B | 2.52 |
| 2016-12-31 | $65.03B | $26.29B | 2.47 |
| 2016-09-30 | $63.32B | $23.23B | 2.73 |
| 2016-06-30 | $66.29B | $21.54B | 3.08 |
| 2016-03-31 | $62.74B | $22.13B | 2.83 |
| 2015-12-31 | $60.21B | $27.75B | 2.17 |
| 2015-09-30 | $63.49B | $25.26B | 2.51 |
| 2015-06-30 | $61.00B | $24.51B | 2.49 |
| 2015-03-31 | $58.19B | $23.84B | 2.44 |
| 2014-12-31 | $55.74B | $25.03B | 2.23 |
| 2014-09-30 | $59.97B | $22.98B | 2.61 |
| 2014-06-30 | $60.12B | $24.36B | 2.47 |
| 2014-03-31 | $57.37B | $23.84B | 2.41 |
| 2013-12-31 | $56.41B | $25.68B | 2.20 |
| 2013-09-30 | $52.18B | $25.84B | 2.02 |
| 2013-06-30 | $51.27B | $23.77B | 2.16 |
| 2013-03-31 | $47.23B | $22.52B | 2.10 |
| 2012-12-31 | $46.12B | $24.26B | 1.90 |
| 2012-09-30 | $44.79B | $23.94B | 1.87 |
| 2012-06-30 | $41.62B | $23.85B | 1.75 |
| 2012-03-31 | $57.01B | $21.20B | 2.69 |
| 2011-12-31 | $54.32B | $22.81B | 2.38 |
| 2011-09-30 | $53.44B | $21.69B | 2.46 |
| 2011-06-30 | $52.67B | $20.99B | 2.51 |
| 2011-03-31 | $49.22B | $24.01B | 2.05 |
| 2010-12-31 | $47.31B | $23.07B | 2.05 |
| 2010-09-30 | $42.72B | $17.41B | 2.45 |
| 2010-06-30 | $39.02B | $17.16B | 2.27 |
| 2010-03-31 | $38.86B | $18.50B | 2.10 |
| 2009-12-31 | $39.54B | $21.73B | 1.82 |
| 2009-09-30 | $35.60B | $19.25B | 1.85 |
| 2009-06-30 | $35.49B | $19.89B | 1.79 |
| 2009-03-31 | $34.84B | $21.33B | 1.63 |
| 2008-12-31 | $34.38B | $20.85B | 1.65 |
| 2008-09-30 | $36.59B | $22.73B | 1.61 |
| 2008-06-30 | $35.82B | $21.78B | 1.64 |
| 2008-03-31 | $33.82B | $22.07B | 1.53 |
| 2007-12-31 | $29.95B | $19.84B | 1.51 |
| 2007-09-30 | $28.94B | $19.33B | 1.50 |
| 2007-06-30 | $25.80B | $18.98B | 1.36 |
| 2007-03-31 | $24.67B | $19.66B | 1.26 |
| 2006-12-31 | $22.98B | $19.16B | 1.20 |
| 2006-09-30 | $31.29B | $12.06B | 2.59 |
| 2006-06-30 | $31.51B | $12.19B | 2.59 |
| 2006-03-31 | $33.75B | $13.19B | 2.56 |
| 2005-12-31 | $31.48B | $12.64B | 2.49 |
| 2005-09-30 | $30.58B | $12.05B | 2.54 |
| 2005-06-30 | $28.72B | $11.64B | 2.47 |
| 2005-03-31 | $28.77B | $12.98B | 2.22 |
| 2004-12-31 | $27.32B | $13.93B | 1.96 |
| 2004-09-30 | $26.82B | $12.33B | 2.18 |
| 2004-06-30 | $24.66B | $12.06B | 2.04 |
| 2004-03-31 | $24.36B | $12.45B | 1.96 |
| 2003-12-31 | $23.00B | $13.45B | 1.71 |
| 2003-09-30 | $22.15B | $12.78B | 1.73 |
| 2003-06-30 | $21.38B | $12.84B | 1.67 |
| 2003-03-31 | $20.47B | $11.46B | 1.79 |
| 2002-12-31 | $19.27B | $11.45B | 1.68 |
| 2002-09-30 | $19.00B | $10.70B | 1.78 |
| 2002-06-30 | $18.85B | $10.57B | 1.78 |
| 2002-03-31 | $18.42B | $8.30B | 2.22 |
| 2001-12-31 | $18.47B | $8.04B | 2.30 |
| 2001-09-30 | $19.08B | $7.50B | 2.54 |
| 2001-06-30 | $18.19B | $7.35B | 2.48 |
| 2001-03-31 | $16.42B | $6.82B | 2.41 |
| 2000-12-31 | $16.69B | $7.26B | 2.30 |
| 2000-09-30 | $15.23B | $6.67B | 2.28 |
| 2000-06-30 | $14.37B | $6.61B | 2.18 |
| 2000-03-31 | $13.98B | $7.13B | 1.96 |
| 1999-12-31 | $13.20B | $7.45B | 1.77 |
| 1999-09-30 | $12.86B | $6.98B | 1.84 |
| 1999-06-30 | $12.15B | $7.89B | 1.54 |
| 1999-03-31 | $11.62B | $7.87B | 1.48 |
| 1998-12-31 | $11.13B | $8.16B | 1.36 |
| 1998-09-30 | $12.18B | $5.40B | 2.26 |
| 1998-06-30 | $11.34B | $5.14B | 2.21 |
| 1998-03-31 | $11.13B | $5.22B | 2.14 |
| 1997-12-31 | $10.56B | $5.28B | 2.00 |
| 1997-09-30 | $11.14B | $5.48B | 2.03 |
| 1997-06-30 | $10.27B | $5.31B | 1.93 |
| 1997-03-31 | $9.97B | $5.45B | 1.83 |
| 1996-12-31 | $9.37B | $5.18B | 1.81 |
| 1996-09-30 | $9.60B | $4.93B | 1.95 |
| 1996-06-30 | $9.24B | $4.40B | 2.10 |
| 1996-03-31 | $9.00B | $4.42B | 2.04 |
| 1995-12-31 | $7.94B | $4.39B | 1.81 |
| 1995-09-30 | $8.08B | $4.31B | 1.88 |
| 1995-06-30 | $7.84B | $4.29B | 1.83 |
| 1995-03-31 | $7.56B | $4.17B | 1.81 |
| 1994-12-31 | $6.68B | $4.27B | 1.57 |
| 1994-09-30 | $6.66B | $4.41B | 1.51 |
| 1994-06-30 | $6.12B | $3.20B | 1.91 |
| 1994-03-31 | $5.67B | $3.15B | 1.80 |
| 1993-12-31 | $5.22B | $3.21B | 1.62 |
| 1993-09-30 | $5.64B | $3.34B | 1.69 |
| 1993-06-30 | $5.58B | $3.04B | 1.84 |
| 1993-03-31 | $5.43B | $3.15B | 1.73 |
| 1992-12-31 | $5.42B | $3.43B | 1.58 |
| 1992-09-30 | $5.90B | $3.29B | 1.80 |
| 1992-06-30 | $5.45B | $3.35B | 1.63 |
| 1992-03-31 | $4.95B | $2.76B | 1.79 |
| 1991-12-31 | $4.93B | $2.69B | 1.84 |
| 1991-09-30 | $4.76B | $2.39B | 1.99 |
| 1991-06-30 | $4.60B | $2.53B | 1.82 |
| 1991-03-31 | $4.55B | $2.30B | 1.98 |
| 1990-12-31 | $4.66B | $2.62B | 1.78 |
| 1990-09-30 | $4.91B | $2.92B | 1.68 |
| 1990-06-30 | $4.68B | $2.82B | 1.66 |
| 1990-03-31 | $4.19B | $2.57B | 1.63 |
| 1989-12-31 | $3.78B | $1.93B | 1.96 |
| 1989-09-30 | $3.75B | $1.84B | 2.04 |
| 1989-06-30 | $3.86B | $2.12B | 1.82 |
| 1989-03-31 | $3.68B | $1.94B | 1.90 |
| 1988-12-31 | $3.50B | $1.87B | 1.88 |
| 1988-09-30 | $3.50B | $2.16B | 1.62 |
| 1988-06-30 | $3.75B | $2.24B | 1.68 |
| 1988-03-31 | $3.66B | $2.00B | 1.83 |
| 1987-12-31 | $3.27B | $1.76B | 1.86 |
| 1987-09-30 | $3.64B | $2.14B | 1.70 |
| 1987-06-30 | $3.47B | $2.54B | 1.37 |
| 1987-03-31 | $3.22B | $2.42B | 1.33 |
| 1986-12-31 | $3.20B | $2.29B | 1.40 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |